Nine Point Two Capital LLC Arcus Biosciences, Inc. Transaction History

Nine Point Two Capital LLC

  • $252 Million
  • Q4 2023

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023
BUY
$15.96 - $23.15 $254,019 - $368,455
15,916 New
15,916 $290,000
Q3 2022

Nov 14, 2022
SELL
$23.23 - $30.07 $202,193 - $261,729
-8,704 Reduced 49.92%
8,732 $228,000
Q2 2022

Aug 15, 2022
BUY
$17.23 - $37.73 $300,422 - $657,860
17,436 New
17,436 $441,000

Others Institutions Holding RCUS

# of Institutions
200
Shares Held
51.5M
Call Options Held
236K
Put Options Held
141K
View Full List

About Arcus Biosciences, Inc.

RCUS Quotes by TradingView
  • Ticker RCUS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 72,160,000
  • Market Cap $950M
  • Description
  • Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...
More about RCUS
Track This Portfolio

Track Nine Point Two Capital LLC Portfolio

Follow Nine Point Two Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nine Point Two Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nine Point Two Capital LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email